12 trials were included in this Cochrane review of molecularly targeted therapies and immunotherapies as adjuncts to standard treatments for oral cancer. Moderate evidence was found that standard therapy plus epidermal growth factor receptor monoclonal antibody (EGFR mAb) reduced mortality and locoregional failures.